@article{9a7972fdd2a844b28b64551da8ed3629,
title = "Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)–associated membranous nephropathy",
abstract = "Lipoic acid (alpha lipoic acid, thioctic acid) is a popular over-the-counter antioxidant and insulin-mimetic supplement under investigation in a variety of conditions including multiple sclerosis, diabetes, and schizophrenia. Unfortunately, high-grade proteinuria was an unexpected adverse event specific to the treatment arm of our clinical trial investigating lipoic acid supplementation in patients with multiple sclerosis. This observation led to detection of similar patients in our nephrology practice. Here, we describe four biopsy-proven cases of neural epidermal growth factor-like 1 (NELL1)–associated membranous nephropathy following lipoic acid supplementation and a fifth suspected case. Discontinuation of lipoic acid and supportive therapy resulted in remission.",
keywords = "albuminuria, glomerulonephritis, kidney biopsy, kidney pathology, lipoic acid, membranous nephropathy, nephrotic syndrome, proteinuria",
author = "Spain, {Rebecca I.} and Andeen, {Nicole K.} and Gibson, {Pamela C.} and Samuels, {Mary H.} and Morris, {Cynthia D.} and Solomon, {Andrew J.} and Richard Solomon and Carin Waslo and Avasare, {Rupali S.}",
note = "Funding Information: Support for this study came from the Department of Veterans Affairs ( I01 RX002682-01 ; B7493-W ), the National Multiple Sclerosis Society ( R-1705-27628 ), the Multiple Sclerosis Society of Canada ( 1073-A-4 ), and the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), through Grant Award Number UL1TR002369 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Funding Information: RIS has research grant funding from Department of Veterans Affairs, National MS Society, and Multiple Sclerosis Society of Canada. AJS receives consulting fees from EMD Serono, Genentech, Biogen, Alexion, Celgene, and Greenwich Biosciences; does nonpromotional speaking for EMD Serono; and conducts contracted research for Sanofi, Biogen, Novartis, Alexion, and Genentech. RSA is the nephrology consultant on the Data Safety and Monitoring Board for the Lipoic Acid in Progressive Multiple Sclerosis study ( NCT03161028 ). All the other authors declared no competing interests. Publisher Copyright: {\textcopyright} 2021",
year = "2021",
month = dec,
doi = "10.1016/j.kint.2021.10.010",
language = "English (US)",
volume = "100",
pages = "1208--1213",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "6",
}